Astellas Pharma (OTCMKTS:ALPMY) Reaches New 12-Month Low – Should You Sell?

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s stock price hit a new 52-week low on Thursday . The stock traded as low as $8.55 and last traded at $9.01, with a volume of 790563 shares changing hands. The stock had previously closed at $8.99.

Astellas Pharma Price Performance

The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 0.39. The stock has a fifty day simple moving average of $9.62 and a 200-day simple moving average of $10.20. The stock has a market cap of $16.00 billion, a price-to-earnings ratio of -40.18 and a beta of 0.31.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share (EPS) for the quarter. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. As a group, equities research analysts expect that Astellas Pharma Inc. will post 0.42 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.